On September 22, 2025 Tubulis reported that its late-breaking abstract covering first clinical data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for oral presentation at the upcoming European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, being held October 17-21, 2025, in Berlin (Press release, Tubulis, SEP 22, 2025, View Source [SID1234656162]). The presentation by the principal investigator of the study, Dr. Antonio Gonzalez-Martin, will provide interim data from the dose escalation part of the ovarian cancer cohort in the first-in-human study with TUB-040. Tubulis’ lead antibody-drug conjugate (ADC), TUB-040 is a next-generation NaPi2b-targeting ADC developed using Tubulis’ proprietary Tubutecan linker-payload platform. It combines the company’s P5 conjugation system with an exatecan payload enabling the development of stable, highly targeted ADCs, optimized for the on-target delivery of the topoisomerase-1 inhibitor while minimizing systemic toxicity. In a range of preclinical models, including ovarian cancer, TUB-040 demonstrated superior biophysical properties as well as effective and durable responses.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the oral presentation:
Title: NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high-grade serous carcinoma (HGSC)
Presenter: Dr. Antonio Gonzalez-Martin, Director Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra
Session Category and Title: Mini Oral session: Gynaecological cancers
Session Date and Time: October 19, 2025; 10:15 – 11:45 am CEST
Lecture Time: 10:38 – 10:43 am CEST
Location: Cologne Auditorium – CityCube A
Abstract Number: #5520
About TUB-040 and the Tubutecan Technology
Tubulis’ lead antibody-drug conjugate (ADC) TUB-040 is directed against NaPi2b, an antigen highly overexpressed in ovarian cancer and lung adenocarcinoma. It consists of an IgG1 antibody targeting NaPi2b equipped with Tubulis’ proprietary Tubutecan technology, connecting the Topoisomerase I inhibitor, exatecan, through a cleavable linker system based on the company’s proprietary P5 conjugation technology with a homogeneous DAR of 8. Based on novel chemistry for cysteine-selective conjugation, the technology enables the development of stable, highly targeted ADCs optimized for the on-target delivery of the topoisomerase-1 inhibitor while minimizing systemic toxicity. The candidate is currently being investigated in a multicenter Phase I/IIa study (NAPISTAR1-01, NCT06303505) that aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-040 as a monotherapy in patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).